Experimental rabies vaccines for humans

Expert Review of Vaccines

Volumn 9, Issue 10, 2010, Pages 1177-1186

  McGettigan, James P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

attenuated rabies vaccines; post exposure vaccines; pre exposure vaccines; rabies vaccines; replication deficient vectors; reverse genetics; single cycle vectors

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN G; MATRIX PROTEIN; PHOSPHOPROTEIN; RABIES VACCINE;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; GENETIC PROCEDURES; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; MEDICAL TECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; RABIES; RABIES VIRUS; REVIEW; TREATMENT OUTCOME; VACCINATION; VIRUS REPLICATION;

ANIMALS; ANIMALS, WILD; GENETIC VECTORS; HUMANS; IMMUNIZATION SCHEDULE; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINATION; VACCINES, INACTIVATED; VIRUS REPLICATION;

EID: 77957948788     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.105     Document Type: Review

References (67)

1. Jackson AC. Rabies. Neurolog. Clin. 26(3), 717-726 (2008).
2. WHO. Rabies and Envenomings, a Neglected Public Health Issue. Report of a Consultative Meeting. WHO, Geneva, Switzerland (2007).
3. Blanton JD, Palmer D, Christian KA, Rupprecht CE. Rabies surveillance in the United States during 2007. J. Am. Vet. Med. Assoc. 233(6), 884-897 (2008).
4. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47(3), 401-409 (2008).
5. Turner GS. Immunoglobulin (IgG) and (IgM) antibody responses to rabies vaccine. J. Gen. Virol. 40, 595-604 (1978).
6. + T cells in murine resistance to street rabies virus. J. Virol. 65(7), 3429-3434 (1991).
7. Brinkman DM, Jol-van der Zijde CM, ten Dam MM et al. Vaccination with rabies to study the humoral and cellular immune response to a T-cell dependent neoantigen in man. J. Clin. Immunol. 23(6), 528-538 (2003).
8. Perrin P, Joffret ML, Zanetti C et al. Rabies-specific production of interleukin-2 by peripheral blood lymphocytes from human rabies vaccinees. Vaccine 9(8), 549-558 (1991).
9. Uytdehaag FG, Osterhaus AD, Loggen HG et al. Induction of antigen-specific antibody response in human peripheral blood lymphocytes in vitro by a dog kidney cell vaccine against rabies virus (DKCV). J. Immunol. (Baltimore) 131(3), 1234-1239 (1983).
10. Moore SM, Wilkerson MJ, Davis RD, Wyatt CR, Briggs DJ. Detection of cellular immunity to rabies antigens in human vaccinees. J. Clin. Immunol. 26(6), 533-545 (2006).
11. Blanchard-Rohner G, Pulickal AS, Jol-van der Zijde CM, Snape MD, Pollard AJ. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 114(24), 4998-5002 (2009).
12. Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine 23(11), 1414-1425 (2005).
13. Otvos L Jr, Hollosi M, Perczel A, Dietzschold B, Fasman GD. Phosphorylation loops in synthetic peptides of the human neurofilament protein middle-sized subunit. J. Protein Chem. 7(4), 365-376 (1988).
14. Johnson N, Cunningham AF, Fooks AR. The immune response to rabies virus infection and vaccination. Vaccine 28(23), 3896-3901 (2010).
15. WHO. WHO Position Paper on rabies vaccines. Weekly Epidemiol. Record 82(49/50), 425-436 (2007).
16. Rupprecht CE, Briggs D, Brown CM et al. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Weekly Rep. 59(RR-2), 1-9 (2010).
17. Warrell MJ, Suntharasamai P, Nicholson KG et al. Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens. Lancet 1(8382), 874-876 (1984).
18. Suntharasamai P, Warrell MJ, Viravan C et al. Purified chick embryo cell rabies vaccine: economical multisite intradermal regimen for post-exposure prophylaxis. Epidemiol. Infect. 99(3), 755-765 (1987).
19. Lang J, Hoa DQ, Gioi NV et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an expanded programme on immunizationsession in Viet Nam: results of a comparative randomized trial. Trans. Royal Soc. Trop. Med. Hygiene 93(2), 208-213 (1999).
20. Warrell MJ, Riddell A, Yu LM et al. A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Neglect. Trop. Dis. 2(4), e224 (2008).
21. Strady C, Andreoletti L, Baumard S et al. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans. Royal Soc. Trop. Med. Hygiene 103(11), 1159-1164 (2009).
22. Cenna J, Tan GS, Papaneri AB et al. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26(50), 6405-6414 (2008).
23. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant - the long and winding road . Drug Discov. Today 14(11-12), 541-551 (2009).
24. Ertl HC. Novel vaccines to human rabies. PLoS Neglect. Trop. Dis. (Electronic Resource) 3(9), e515 (2009).
25. Wang X, Bao M, Wan M et al. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine 26(15), 1893-1901 (2008).
26. Ramya R, Verma PC, Chaturvedi VK et al. Poly(lactide-co-glycolide) microspheres: a potent oral delivery system to elicit systemic immune response against inactivated rabies virus. Vaccine 27(15), 2138-2143 (2009).
27. Chulasugandha P, Khawplod P, Havanond P, Wilde H. Cost comparison of rabies pre-exposure vaccination with post-exposure treatment in Thai children. Vaccine 24(9), 1478-1482 (2006).
28. Kamoltham T, Thinyounyong W, Phongchamnaphai P et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J. Pediatrics 151(2), 173-177 (2007).
29. Lang J, Duong GH, Nguyen VG et al. Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. Lancet 349(9066), 1663-1665 (1997).
30. Lang J, Feroldi E, Vien NC. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam. J. Trop. Pediatrics 55(1), 26-31 (2009).
31. Lumbiganon P, Chaiprasithikul P, Sookpranee T, Paholpak S, Wasi C. Pre-exposure vaccination with purified chick embryo cell rabies vaccines in children. Asian Pacif. J. Allergy Immunol. 7(2), 99-101 (1989).
32. Pengsaa K, Limkittikul K, Sabchareon A et al. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pediatr. Infect. Dis. J. 28(4), 335-337 (2009).
33. Shanbag P, Shah N, Kulkarni M et al. Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). Hum. Vaccines 4(5), 365-369 (2008).
34. Dodet B, Asian Rabies Expert B. An important date in rabies history. Vaccine 25(52), 8647-8650 (2007).
35. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8(20), 934-943 (2003).
36. Weyer J, Rupprecht CE, Nel LH. Poxvirus-vectored vaccines for rabies - a review. Vaccine 27(51), 7198-7201 (2009).
37. Ertl HC. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin. Biol. Ther. 3(4), 639-644 (2003).
38. Schnell MJ, McGettigan JP, Wirblich C, Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat. Rev. Microbiol. 8(1), 51-61 (2010).
39. Wunner WH. Rabies Virus. Jackson AC, Wunner WH (Eds). Elsevier Science, CA, USA (2007).
40. Schnell MJ, Mebatsion T, Conzelmann KK. Infectious rabies viruses from cloned cDNA. EMBO J. 13(18), 4195-4203 (1994).
41. McGettigan JP, Pomerantz RJ, Siler CA et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 77(1), 237-244 (2003).
42. Faul EJ, Aye PP, Papaneri AB et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 28(2), 299-308 (2009).
43. McKenna PM, Koser ML, Carlson KR et al. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis. 195(7), 980-988 (2007).
44. Dietzschold B, Fields BN. Rhabdoviruses. In: Fields Virology. Lippincott-Raven Publishers, PA, USA, 1137-1152 (1996).
45. Rose JK, Schubert M. Rhabdovirus Genomes and Their Products. Wagner RR (Ed.). Plenum Publishing Corp., NY, USA (1987).
46. Brzozka K, Finke S, Conzelmann KK. Identification of the rabies virus a/b interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 7673-7681 (2005).
47. Brzozka K, Finke S, Conzelmann KK. Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol. 80(6), 2675-2683 (2006).
48. Shoji Y, Inoue S, Nakamichi K et al. Generation and characterization of P gene-deficient rabies virus. Virology 318(1), 295-305; 295-305 (2004).
49. Faber M, Pulmanausahakul R, Hodawadekar SS et al. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 76(7), 3374-3381 (2002).
50. Megret F, Prehaud C, Lafage M et al. Immunopotentiation of the antibody response against influenza HA with apoptotic bodies generated by rabies virus G-ERA protein-driven apoptosis. Vaccine 16(23), 5342-5350 (2005).
51. Mebatsion T, Weiland F, Conzelmann KK. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 73(1), 242-250 (1999).
52. Cenna J, Hunter M, Tan GS et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 200(8), 1251-1260 (2009).
53. Ito N, Sugiyama M, Yamada K et al. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol. 49(11), 971-979 (2005).
54. Shearer MH, Dark RD, Chodosh J, Kennedy RC. Comparison and characterization of immunoglobulin G subclasses among primate species. Clin. Diag. Lab. Immunol. 6(6), 953-958 (1999).
55. Burton DR. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2(9), 706-713 (2002).
56. Phares TW, Kean RB, Mikheeva T, Hooper DC. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. (Baltimore) 176(12), 7666-7675 (2006).
57. Mebatsion T, Konig M, Conzelmann KK. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 84(6), 941-951 (1996).
58. Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 84(6), 2820-2831 (2010).
59. Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol. 3(6), 493-502 (2003).
60. Hooper DC, Phares TW, Fabis MJ, Roy A. The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Neglect. Trop. Dis. (Electronic Resource) 3(10), e535 (2009).
61. Baer GM, Shaddock JH, Williams LW. Prolonging morbidity in rabid dogs by intrathecal injection of attenuated rabies vaccine. Infect. Immun. 12(1), 98-103 (1975).
62. Faber M, Li J, Kean RB et al. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106(27), 11300-11305 (2009).
63. Zhao L, Toriumi H, Kuang Y, Chen H, Fu ZF. The roles of chemokines in rabies virus infection: overexpression may not always be beneficial. J. Virol. 83(22), 11808-11818 (2009).
64. Belotto A, Leanes LF, Schneider MC, Tamayo H, Correa E. Overview of rabies in the Americas. Virus Res. 111(1), 5-12 (2005).
65. Lembo T, Hampson K, Kaare MT et al. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl. Trop. Dis. 4(2), e626 (2010).
66. Schneider MC, Belotto A, Ade MP et al. Current status of human rabies transmitted by dogs in Latin America. Cad Saude Publica 23(9), 2049-2063 (2007).
67. Baer GM. The history of rabies. In: Rabies. Jackson AC, Wunner WH (Eds). Elsevier Science CA, USA, 11-19 (2007).